Bronchogen is a synthetic tetrapeptide — Ala-Glu-Asp-Leu (AEDL) — developed by Professor Vladimir Khavinson as the lung-specific bioregulator in the Cytogen series. Its tissue target is the bronchial epithelium — the mucosal lining of the airways. It occupies a specific niche in the bioregulator series: not a systemic longevity compound, but a targeted organ-maintenance peptide for the respiratory system.
The lung is one of the highest-turnover organs in the body — bronchial epithelial cells are constantly exposed to environmental insults: pollution, infection, smoking, allergens, oxidative stress. Over decades, cumulative damage and reduced regenerative capacity result in declining respiratory function. Bronchogen is designed to support the regenerative machinery of the airway epithelium directly.
In the Khavinson framework, each organ has its own aging clock — and the lungs are no exception. Bronchogen addresses this clock specifically, without attempting to be a systemic longevity compound.
How it works
Bronchial Epithelial Chromatin Interaction
Consistent with the Khavinson bioregulator model, Bronchogen is proposed to penetrate bronchial epithelial cell nuclei and interact with chromatin — regulating gene expression programs specific to airway tissue. This epigenetic modulation is hypothesized to promote regeneration and cellular repair in the bronchial lining.
Anti-Inflammatory Signaling in Airways
Cell studies show Bronchogen modulates inflammatory cytokine production in bronchial epithelial cells, reducing pro-inflammatory signaling without blanket immunosuppression. This targeted anti-inflammatory effect may be important for conditions characterized by chronic airway inflammation.
Epithelial Regeneration and Mucus Regulation
Animal studies demonstrate Bronchogen promotes regeneration of damaged bronchial epithelium and supports healthy mucus secretion patterns. The bronchial epithelium is the front-line barrier between the external environment and the bloodstream — maintaining its integrity is fundamental to respiratory health.
What the research shows
NOTE — PRIMARILY KHAVINSON GROUP DATA · SMALL CLINICAL STUDIES · NO WESTERN RCTS
STUDYRussian Pulmonology Journal · 2005
Bronchogen as Adjunct in COPD Management
Khavinson VK et al.
COPD patients receiving Bronchogen alongside standard treatment showed improved spirometry parameters and quality of life scores vs. standard treatment alone at 6-month follow-up. Bronchial epithelial biopsy findings suggested reduced inflammatory infiltration in the treated group.
STUDYBulletin of Experimental Biology and Medicine · 2003
Bronchogen (AEDL) Effects on Bronchial Epithelial Cell Proliferation and Apoptosis
Khavinson VK et al.
Bronchogen stimulated proliferation of bronchial epithelial cells in culture and protected against oxidative stress-induced apoptosis. Gene expression changes included upregulation of epithelial repair genes and downregulation of pro-inflammatory mediators.
Lung Protection in Aged Animals with AEDL Tetrapeptide
Khavinson VK et al.
Bronchogen administration in aged rats reduced markers of bronchial epithelial aging (cellular senescence markers, inflammatory infiltration, fibrotic changes) and preserved respiratory function compared to untreated aged controls. The effect was most pronounced in animals with the highest baseline aging scores.
Bronchogen has moderate biohacker interest, concentrated among people with respiratory history — former or current smokers, occupational lung exposure, post-COVID respiratory sequelae, or asthma/COPD. It is rarely a first-choice compound for general longevity protocols given its narrow organ focus.
Community protocols typically follow Khavinson's clinical approach: 10–20 mcg/day for 10 days, 1–2 times per year. Some users report improved breathing and reduced shortness of breath — but these are anecdotal in populations that would benefit from any lung-supportive intervention, making attribution difficult.
WHAT THE RESEARCH SHOWS
✓KNOWN
✓Bronchogen (AEDL) is the lung-specific Cytogen — targeted to bronchial epithelial tissue with documented organ specificity
✓Cell studies show proliferative and anti-apoptotic effects on bronchial epithelial cells
✓Animal studies show protection against lung aging markers (senescence, inflammation, fibrosis)
✓Small human clinical data from Russian COPD studies shows spirometry improvement as adjunct therapy
✓Well-tolerated — no serious adverse events in available clinical data
?UNCERTAIN
?Whether Bronchogen produces measurable respiratory benefit in healthy people without existing lung pathology
?Optimal dosing for preventive vs. therapeutic use — protocols are extrapolated from small clinical studies
?Whether COPD effects translate to other forms of lung damage or general respiratory aging
?Independent Western-standard RCT data — all clinical evidence is from Russian sources
?Whether Bronchogen or Taxorest (the Cytomax equivalent) produces superior outcomes for different use cases
RECONSTITUTION CALCULATOR
EDUCATIONAL TOOL — NOT MEDICAL ADVICE · VERIFY WITH YOUR CLINICIAN
AI COACH PREVIEW
I'm a 52-year-old former smoker. I quit 8 years ago but still have reduced lung capacity. Would Bronchogen help, and how would I integrate it into a broader bioregulator protocol?
For a former smoker with documented reduced capacity, Bronchogen is one of the more compelling uses in the bioregulator series — this is exactly the kind of accumulated damage it's designed to address. The lung epithelium has real regenerative capacity; the question is whether you can signal it appropriately. A reasonable approach: 20 mcg/day SC for 10 days, twice yearly (spring and autumn). If you want to address the mucosal angle more broadly — both airway and gut epithelium — Chonluten (GEP) is worth considering alongside or as an alternative for one of the cycles. For systemic longevity, run Epithalon + Thymalin annually as your foundation. With a respiratory-specific concern, Bronchogen becomes a meaningful addition rather than a stretch.
CONTINUE IN THE APP
Open PepperLedger to ask the Coach about Bronchogen and respiratory bioregulator protocols →
Free to join. The Coach understands the full Khavinson bioregulator system and can help you determine if Bronchogen fits your protocol.
Free to join · No credit card · 23-day Pro trial included